Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 15 Apr 2010 |
| Amendment of Section 12 of Articles of Association entered in the Trade Register | 8 Apr 2010 |
| Orion comments on FDA release on Stalevo | 1 Apr 2010 |
| Orion Corporation: Decisions by the AGM on 24 March 2010 | 24 Mar 2010 |
| Orion Corporation: Matti Kavetvuo Vice Chairman of the Board of Directors. Compositions of Board committees | 24 Mar 2010 |